Millie Nelson

Contributor at BioProcess International Magazine

Featured in: Favicon

bioprocessintl.com Favicon

einnews.com Favicon

xconomy.com

Articles

SiteOne, sold! Lilly bags non-opioid pain startup for up to $1bn

1 week ago | bioxconomy.com | Millie Nelson

Eli Lilly will expand its pain pipeline through the acquisition of SiteOne, adding Phase II-ready Nav1.8 inhibitor STC-004. While the upfront payment remains undisclosed, Lilly's deal with SiteOne Therapeutics – a private biotech specializing in sodium channel inhibitors for pain and neuronal hyperexcitability disorders – could ultimately reach $1 billion in cash payments.
Sanofi buys Vigil Neuroscience for $470m

2 weeks ago | bioxconomy.com | Millie Nelson

Sanofi's initial $40 million investment in Vigil has evolved into a complete acquisition, bringing the Alzheimer's drug candidate VG-3927 under its corporate umbrella. The clinical-stage biotech company Vigil used its $40 million investment from Sanofi to drive its R&D plans. Fast forward just shy of one year, the French firm has decided to acquire Vigil for $470 million and will add oral small molecule TREM2 agonist VG-3927 to its portfolio.
EsoBiotec's success story

2 weeks ago | bioxconomy.com | Millie Nelson

Jean-Pierre Latere, CEO of EsoBiotec, reflects on his journey from capital constraint to inking an M&A deal worth up to $1 billion with AstraZeneca. The deal, which has now closed, saw pharma giant AstraZeneca pay cell therapy firm EsoBiotec $425 million upfront and up to $575 million in capital based on specific development and regulatory milestones. However, Latere did not follow the traditional biotech founder’s trajectory.
With VC firm on board, Huma's M&A strategy takes shape

2 weeks ago | bioxconomy.com | Millie Nelson

Having partnered with VC firm Eckuity, digital health firm Huma discusses its two-pronged growth strategy including the acquisition of respiratory health specialist Aluna. The firm has bought California-based remote monitoring and management company Aluna (also known as Knox Medical Diagnostics), for an undisclosed fee. Aluna's spirometers and respiratory monitoring technology will come under Huma's umbrella while adding over 150 US-based health systems and clinic networks to its global footprint.
Vugene's $1.1m grant

2 weeks ago | bioxconomy.com | Millie Nelson

Finnish VC firm Superhero Capital leads $1.1 million investment in Vugene, backing its strategic move from service provider to service-as-a-software. Vugene, a Lithuanian multi-omics data analysis firm, has secured €1 million ($1.1 million) in funding led by Finnish venture capital firm Superhero Capital.
Metabolic medicine maker scores $147m in Series B round

3 weeks ago | bioxconomy.com | Millie Nelson

The €132 million ($147 million) funding round was led by Jeito Capital, co-led by Forbion Growth, and saw additional contribution from Seroba, Pictet Group, and existing investors Forbion Ventures, Schroders Capital, and BioGeneration Ventures (BGV).
Balancing scientific excellence with investment realities

4 weeks ago | bioxconomy.com | Millie Nelson

Experts across the board have raised their concern about Europe lagging behind the US and other regional players in the life sciences space. The worries range from (but are not limited to) dwindling clinical trial numbers, aversity to risk, patient access issues, and the volume of funding.
$800m Novartis-Regulus deal eyes kidney disease cure

1 month ago | bioxconomy.com | Dan Stanton |Millie Nelson

The acquisition of Regulus Therapeutics will bolster both Novartis’s renal disease portfolio and its presence in the microRNA space. Likely to close in the second half of 2025, the deal sees Swiss Biopharma giant Novartis pay $800 million upfront to acquire San Diego, California-based Regulus Therapeutics. A further $900 million could be paid depending on future regulatory milestones.
Merck KGaA’s $3.9bn acquisition of SpringWorks

1 month ago | bioxconomy.com | Millie Nelson

Germany’s Merck will bolster its rare tumor pipeline through the acquisition of US biotech SpringWorks Therapeutics for approximately $3.9 billion. The deal sees Merck fork out $47 per share in cash for Connecticut-based Pfizer spinout SpringWorks. Melanie Howard, partner at Latham & Watkins, commented on the “interesting deal environment” the biotech sector is currently witnessing at LSX World Congress Europe in London, UK.
Attovia pockets $90m in Series C funding

1 month ago | bioxconomy.com | Millie Nelson

Attovia Therapeutics has closed a $90 million Series C financing round to advance its lead assets for inflammatory and immune (I&I) diseases. This marks the second fundraising round clinical-stage biopharma firm Attovia has closed in three years. The financing will be used to fund early-to-mid-stage clinical studies for ATTO-1310 for the treatment of chronic pruritus and ATTO-3712 in atopic dermatitis, as well as numerous earlier-stage multi-specific programs.